After starting and after each dose increase, tirzepatide can cut the peak absorption of an oral contraceptive by more than half, so the label guidance is a non-oral method or added barrier protection for four weeks after starting and four weeks after each increase. It is a first-dose-and-escalation effect, not a permanent block on all oral drugs
The mechanism depends on the specific peptide: some enhance immune surveillance
Furthermore, the subject matter is very diverse, as peptides are an extremely broad topic in the literature, despite the inclusion criteria that narrow the field of interest and focus on future therapeutic prospects
Serious adverse events were low and comparable to placebo in most analyses
Food and Drug Administration (FDA) for safety or efficacy
He was SUPER nice, knowledgeable, professional, and funny